Is VTRS or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.79% 20.02% 8.02% Belite Bio N/A -11.84% -11.62%

Does the media favor VTRS or BLTE?

In the previous week, Viatris had 13 more articles in the media than Belite Bio. MarketBeat recorded 15 mentions for Viatris and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.91 beat Viatris' score of 0.26 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 3 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to JAZZ or BLTE?

In the previous week, Jazz Pharmaceuticals had 10 more articles in the media than Belite Bio. MarketBeat recorded 12 mentions for Jazz Pharmaceuticals and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.91 beat Jazz Pharmaceuticals' score of 0.21 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BLTE or NBIX?

In the previous week, Neurocrine Biosciences had 8 more articles in the media than Belite Bio. MarketBeat recorded 10 mentions for Neurocrine Biosciences and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.91 beat Neurocrine Biosciences' score of 0.57 indicating that Belite Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CORT or BLTE?

In the previous week, Corcept Therapeutics had 6 more articles in the media than Belite Bio. MarketBeat recorded 8 mentions for Corcept Therapeutics and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.91 beat Corcept Therapeutics' score of 0.48 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ELAN or BLTE?

In the previous week, Elanco Animal Health had 7 more articles in the media than Belite Bio. MarketBeat recorded 9 mentions for Elanco Animal Health and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.91 beat Elanco Animal Health's score of 0.43 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Belite Bio (BLTE) Competitors

$152.72 +0.85 (+0.56%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$152.62 -0.10 (-0.07%)

As of 07:09 AM Eastern

Compare

BLTE vs. VTRS, JAZZ, NBIX, CORT, and ELAN

Should you buy Belite Bio stock or one of its competitors? Belite Bio's main competitors and comparable companies include Viatris (VTRS), Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (NBIX), Corcept Therapeutics (CORT), and Elanco Animal Health (ELAN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Belite Bio compare to Viatris?

Viatris (NASDAQ:VTRS) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Belite Bio has a net margin of 0.00% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.79%	20.02%	8.02%
Belite Bio	N/A	-11.84%	-11.62%

79.9% of Viatris shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Viatris has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, meaning that its stock price is 223% less volatile than the broader market.

Viatris presently has a consensus price target of $20.50, indicating a potential upside of 17.55%. Belite Bio has a consensus price target of $218.73, indicating a potential upside of 43.22%. Given Belite Bio's stronger consensus rating and higher probable upside, analysts plainly believe Belite Bio is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Belite Bio has lower revenue, but higher earnings than Viatris. Belite Bio is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.40	-$3.51B	-$0.36	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

In the previous week, Viatris had 13 more articles in the media than Belite Bio. MarketBeat recorded 15 mentions for Viatris and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.91 beat Viatris' score of 0.26 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	3 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Viatris beats Belite Bio on 8 of the 15 factors compared between the two stocks.

How does Belite Bio compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Belite Bio has lower revenue, but higher earnings than Jazz Pharmaceuticals. Belite Bio is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.19	-$356.15M	$14.50	14.46
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

Jazz Pharmaceuticals presently has a consensus target price of $291.25, suggesting a potential upside of 38.92%. Belite Bio has a consensus target price of $218.73, suggesting a potential upside of 43.22%. Given Belite Bio's higher possible upside, analysts plainly believe Belite Bio is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	3.00
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Jazz Pharmaceuticals had 10 more articles in the media than Belite Bio. MarketBeat recorded 12 mentions for Jazz Pharmaceuticals and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.91 beat Jazz Pharmaceuticals' score of 0.21 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jazz Pharmaceuticals has a net margin of 20.45% compared to Belite Bio's net margin of 0.00%. Jazz Pharmaceuticals' return on equity of 33.97% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
Belite Bio	N/A	-11.84%	-11.62%

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 4.1% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Jazz Pharmaceuticals has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, indicating that its stock price is 223% less volatile than the broader market.

Summary

Jazz Pharmaceuticals beats Belite Bio on 12 of the 16 factors compared between the two stocks.

How does Belite Bio compare to Neurocrine Biosciences?

Belite Bio (NASDAQ:BLTE) and Neurocrine Biosciences (NASDAQ:NBIX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Neurocrine Biosciences has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Neurocrine Biosciences	$2.86B	4.83	$478.60M	$6.82	19.93

Belite Bio presently has a consensus target price of $218.73, suggesting a potential upside of 43.22%. Neurocrine Biosciences has a consensus target price of $201.14, suggesting a potential upside of 47.99%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Neurocrine Biosciences is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Neurocrine Biosciences	0 Sell rating(s)	5 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.83

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Neurocrine Biosciences had 8 more articles in the media than Belite Bio. MarketBeat recorded 10 mentions for Neurocrine Biosciences and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.91 beat Neurocrine Biosciences' score of 0.57 indicating that Belite Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Belite Bio has a beta of -1.23, indicating that its stock price is 223% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

Neurocrine Biosciences has a net margin of 20.91% compared to Belite Bio's net margin of 0.00%. Neurocrine Biosciences' return on equity of 22.43% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Neurocrine Biosciences	20.91%	22.43%	15.64%

Summary

Neurocrine Biosciences beats Belite Bio on 14 of the 16 factors compared between the two stocks.

How does Belite Bio compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Corcept Therapeutics has a net margin of 6.52% compared to Belite Bio's net margin of 0.00%. Corcept Therapeutics' return on equity of 8.26% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
Belite Bio	N/A	-11.84%	-11.62%

Corcept Therapeutics has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, suggesting that its stock price is 223% less volatile than the broader market.

Corcept Therapeutics currently has a consensus price target of $138.17, indicating a potential upside of 18.87%. Belite Bio has a consensus price target of $218.73, indicating a potential upside of 43.22%. Given Belite Bio's higher probable upside, analysts plainly believe Belite Bio is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Corcept Therapeutics has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	16.50	$99.65M	$0.42	276.74
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

In the previous week, Corcept Therapeutics had 6 more articles in the media than Belite Bio. MarketBeat recorded 8 mentions for Corcept Therapeutics and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.91 beat Corcept Therapeutics' score of 0.48 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Corcept Therapeutics beats Belite Bio on 13 of the 16 factors compared between the two stocks.

How does Belite Bio compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Elanco Animal Health currently has a consensus target price of $29.70, suggesting a potential upside of 31.96%. Belite Bio has a consensus target price of $218.73, suggesting a potential upside of 43.22%. Given Belite Bio's higher possible upside, analysts clearly believe Belite Bio is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Elanco Animal Health has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, indicating that its stock price is 223% less volatile than the broader market.

Belite Bio has a net margin of 0.00% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Belite Bio	N/A	-11.84%	-11.62%

Belite Bio has lower revenue, but higher earnings than Elanco Animal Health. Belite Bio is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.38	-$232M	-$0.41	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Elanco Animal Health had 7 more articles in the media than Belite Bio. MarketBeat recorded 9 mentions for Elanco Animal Health and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.91 beat Elanco Animal Health's score of 0.43 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Elanco Animal Health beats Belite Bio on 10 of the 15 factors compared between the two stocks.

Get Belite Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLTE vs. The Competition

Export

Metric	Belite Bio	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.12B	$12.15B	$7.19B	$13.18B
Dividend Yield	N/A	2.63%	2.52%	19.59%
P/E Ratio	-55.94	680.43	223.62	21.16
Price / Sales	N/A	787.38	547.34	66.59
Price / Cash	N/A	84.08	76.68	52.75
Price / Book	7.44	9.15	10.22	5.92
Net Income	-$77.61M	$2.82B	$3.50B	$380.90M
7 Day Performance	0.13%	-3.76%	-3.50%	-3.90%
1 Month Performance	-9.87%	-7.60%	-7.78%	-6.42%
1 Year Performance	87.94%	-6.10%	0.79%	-6.02%

Belite Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLTE Belite Bio	3.1989 of 5 stars	$152.72 +0.6%	$218.73 +43.2%	+92.7%	$6.12B	N/A	N/A	41	News Coverage
VTRS Viatris	3.2478 of 5 stars	$17.62 0.0%	$20.50 +16.4%	+75.6%	$20.24B	$14.74B	N/A	30,000	Analyst Upgrade
JAZZ Jazz Pharmaceuticals	4.2101 of 5 stars	$231.11 -2.1%	$291.15 +26.0%	+56.7%	$15.00B	$4.27B	15.94	2,890
NBIX Neurocrine Biosciences	4.8178 of 5 stars	$143.22 -0.7%	$202.05 +41.1%	-1.0%	$14.56B	$2.86B	21.00	2,000	Analyst Forecast
CORT Corcept Therapeutics	4.0798 of 5 stars	$118.23 -3.1%	$138.17 +16.9%	+61.2%	$12.78B	$761.41M	281.50	730

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLTE) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Belite Bio (BLTE) Competitors

BLTE vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Belite Bio compare to Viatris?

Summary

How does Belite Bio compare to Jazz Pharmaceuticals?

Summary

How does Belite Bio compare to Neurocrine Biosciences?

Summary

How does Belite Bio compare to Corcept Therapeutics?

Summary

How does Belite Bio compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLTE vs. The Competition

Belite Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Belite Bio (BLTE) Competitors

BLTE vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Belite Bio compare to Viatris?

Is VTRS or BLTE more profitable?

Do insiders and institutionals believe in VTRS or BLTE?

Which has more risk and volatility, VTRS or BLTE?

Do analysts rate VTRS or BLTE?

Which has preferable valuation & earnings, VTRS or BLTE?

Does the media favor VTRS or BLTE?

Summary

How does Belite Bio compare to Jazz Pharmaceuticals?

Which has preferable valuation and earnings, JAZZ or BLTE?

Do analysts recommend JAZZ or BLTE?

Does the media refer more to JAZZ or BLTE?

Is JAZZ or BLTE more profitable?

Do insiders & institutionals hold more shares of JAZZ or BLTE?

Which has more volatility and risk, JAZZ or BLTE?

Summary

How does Belite Bio compare to Neurocrine Biosciences?

Which has stronger valuation & earnings, BLTE or NBIX?

Do analysts prefer BLTE or NBIX?

Do insiders & institutionals hold more shares of BLTE or NBIX?

Does the media prefer BLTE or NBIX?

Which has more risk and volatility, BLTE or NBIX?

Is BLTE or NBIX more profitable?

Summary

How does Belite Bio compare to Corcept Therapeutics?

Is CORT or BLTE more profitable?

Which has more volatility and risk, CORT or BLTE?

Do analysts prefer CORT or BLTE?

Which has stronger valuation and earnings, CORT or BLTE?

Does the media favor CORT or BLTE?

Do institutionals and insiders have more ownership in CORT or BLTE?

Summary

How does Belite Bio compare to Elanco Animal Health?

Do analysts recommend ELAN or BLTE?

Which has more risk and volatility, ELAN or BLTE?

Is ELAN or BLTE more profitable?

Which has higher valuation and earnings, ELAN or BLTE?

Do insiders and institutionals have more ownership in ELAN or BLTE?

Does the media refer more to ELAN or BLTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLTE vs. The Competition

Belite Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools